Samjin Pharmaceuticals Co., Ltd. (KRX: 005500)

Samjin Pharmaceuticals Income Statement

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2022	FY 2021	FY 2012	FY 2011	FY 2010
Period Ending	Dec 31, 2022	Dec 31, 2022	Dec 31, 2021	Dec 31, 2012	Dec 31, 2011	Dec 31, 2010
Operating Revenue	274,032	274,032	250,070	185,702	201,756	200,411
Other Revenue	-0	-0	-0	-	-	-
Revenue	274,032	274,032	250,070	185,702	201,756	200,411
Revenue Growth (YoY)	45.04%	9.58%	34.66%	-7.96%	0.67%	21.18%
Cost of Revenue	156,297	156,297	132,238	77,520	80,316	80,222
Gross Profit	117,734	117,734	117,832	108,182	121,440	120,188
Selling, General & Admin	89,012	89,012	79,494	90,865	97,428	86,293
Research & Development	3,658	3,658	2,582	-	-	8,776
Other Operating Expenses	692.07	692.07	587.29	-	105.36	483.94
Operating Expenses	94,550	94,550	83,921	90,865	97,533	98,108
Operating Income	23,184	23,184	33,911	17,318	23,907	22,080
Interest Expense	-1,763	-1,763	-141.92	-1,770	-2,431	-2,702
Interest & Investment Income	153.52	153.52	215.12	356.69	381.33	1,403
Earnings From Equity Investments	-304.34	-304.34	-25.79	-	-	-
Currency Exchange Gain (Loss)	51.6	51.6	66.93	-	-	-21.1
Other Non Operating Income (Expenses)	483.39	483.39	-191.11	-843.25	-	-79.63
EBT Excluding Unusual Items	21,805	21,805	33,835	15,061	21,857	20,680
Gain (Loss) on Sale of Investments	2,920	2,920	-	-	-	-717.2
Gain (Loss) on Sale of Assets	500.53	500.53	1,037	-	-	149.96
Asset Writedown	0.5	0.5	39.33	-	-	-4,460
Pretax Income	25,226	25,226	34,911	15,061	21,857	15,653
Income Tax Expense	3,325	3,325	6,507	4,422	14,794	5,176
Earnings From Continuing Operations	21,901	21,901	28,404	10,638	7,062	10,477
Minority Interest in Earnings	-7.08	-7.08	-	-	-	-
Net Income	21,894	21,894	28,404	10,638	7,062	10,477
Net Income to Common	21,894	21,894	28,404	10,638	7,062	10,477
Net Income Growth	48.96%	-22.92%	167.00%	50.63%	-32.59%	48.72%
Shares Outstanding (Basic)	13	13	12	13	13	13
Shares Outstanding (Diluted)	13	13	12	13	13	13
Shares Change (YoY)	-2.00%	3.00%	-5.52%	-0.07%	-1.42%	-0.02%
EPS (Basic)	1727.82	1727.82	2308.75	817.00	542.00	792.68
EPS (Diluted)	1727.82	1727.82	2308.75	817.00	542.00	792.68
EPS Growth	52.00%	-25.16%	182.59%	50.74%	-31.62%	48.74%
Free Cash Flow	-18,061	-18,061	-48,581	21,278	1,318	12,921
Free Cash Flow Per Share	-1425.33	-1425.33	-3948.80	1634.08	101.17	977.60
Dividend Per Share	800.000	800.000	800.000	-	-	50.000
Dividend Growth	-	0%	-	-	-	77.12%
Gross Margin	42.96%	42.96%	47.12%	58.26%	60.19%	59.97%
Operating Margin	8.46%	8.46%	13.56%	9.33%	11.85%	11.02%
Profit Margin	7.99%	7.99%	11.36%	5.73%	3.50%	5.23%
Free Cash Flow Margin	-6.59%	-6.59%	-19.43%	11.46%	0.65%	6.45%
EBITDA	33,000	33,000	41,272	21,386	27,149	24,970
EBITDA Margin	12.04%	12.04%	16.50%	11.52%	13.46%	12.46%
D&A For EBITDA	9,816	9,816	7,360	4,069	3,242	2,889
EBIT	23,184	23,184	33,911	17,318	23,907	22,080
EBIT Margin	8.46%	8.46%	13.56%	9.33%	11.85%	11.02%
Effective Tax Rate	13.18%	13.18%	18.64%	29.36%	67.69%	33.06%
Revenue as Reported	-	-	-	-	-	200,411
Advertising Expenses	21,163	21,163	16,485	-	-	13,520

Source: S&P Capital IQ. Standard template. Financial Sources.